FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307291215> ?p ?o ?g. }

• W4307291215 endingPage "S110" @default.
• W4307291215 startingPage "S109" @default.
• W4307291215 abstract "<h3>Purpose/Objective(s)</h3> Emerging data suggest metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET/CT) can detect occult metastatic disease and has been proposed as a biomarker for treatment response. Herein we identify and validate a PSMA-PET biomarker for clinical outcomes following MDT in omCSPC. <h3>Materials/Methods</h3> This was an international multi-institutional retrospective study of two independent cohorts of omCSPC, defined as ≤3 lesions, treated with metastasis-directed stereotactic ablative radiation therapy (SABR). Patients underwent PSMA-PET/CT prior to and 3-6 months after treatment. Pre- and post-SABR PSMA-PET/CT standardized uptake value (SUV) was measured for all lesions and PSMA response defined discretely using a cutpoint of ≥ 30% decrease in SUV_max. PSMA-PET response was correlated with lesion local control (LLC), and metastasis-free survival (MFS), defined per ICECaP working group by a new metastasis on conventional imaging alone (not including pelvic lymph node metastases) or death. <h3>Results</h3> A total of 131 patients (discovery n=35, validation n=96) with 261 treated metastases were included in the analysis, with median follow-up of 29 months (IQR 18.5-41.3). Following SABR, 78.4% of lesions experienced a partial or complete PSMA response. Multivariable analysis demonstrated SUV response significantly associated with improved LLC (HR=0.10, 95%CI 0.04-0.26; p<0.01). Patients with PSMA response in all lesions experienced significantly better MFS (HR=0.37, 95%CI 0.21-0.65; p<0.01) compared to their counterparts, and this maintained significance within both the discovery (p=0.02) and validation (p<0.01) cohorts. <h3>Conclusion</h3> Following SABR, PSMA-PET response is a robust and externally validated radiographic biomarker for MFS in omCSPC. This approach holds promise for guiding clinical management of omCSPC and should be validated as an early response indicator biomarker in localized and other advanced states of prostate cancer." @default.
• W4307291215 created "2022-10-31" @default.
• W4307291215 creator A5005654132 @default.
• W4307291215 creator A5007911776 @default.
• W4307291215 creator A5008266724 @default.
• W4307291215 creator A5008426497 @default.
• W4307291215 creator A5009764655 @default.
• W4307291215 creator A5016032159 @default.
• W4307291215 creator A5017057106 @default.
• W4307291215 creator A5026939990 @default.
• W4307291215 creator A5026973034 @default.
• W4307291215 creator A5032147051 @default.
• W4307291215 creator A5042816161 @default.
• W4307291215 creator A5045520775 @default.
• W4307291215 creator A5047808830 @default.
• W4307291215 creator A5048312605 @default.
• W4307291215 creator A5058612575 @default.
• W4307291215 creator A5061621165 @default.
• W4307291215 creator A5065463553 @default.
• W4307291215 creator A5090124860 @default.
• W4307291215 date "2022-11-01" @default.
• W4307291215 modified "2023-10-16" @default.
• W4307291215 title "Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer" @default.
• W4307291215 doi "https://doi.org/10.1016/j.ijrobp.2022.07.542" @default.
• W4307291215 hasPublicationYear "2022" @default.
• W4307291215 type Work @default.
• W4307291215 citedByCount "0" @default.
• W4307291215 crossrefType "journal-article" @default.
• W4307291215 hasAuthorship W4307291215A5005654132 @default.
• W4307291215 hasAuthorship W4307291215A5007911776 @default.
• W4307291215 hasAuthorship W4307291215A5008266724 @default.
• W4307291215 hasAuthorship W4307291215A5008426497 @default.
• W4307291215 hasAuthorship W4307291215A5009764655 @default.
• W4307291215 hasAuthorship W4307291215A5016032159 @default.
• W4307291215 hasAuthorship W4307291215A5017057106 @default.
• W4307291215 hasAuthorship W4307291215A5026939990 @default.
• W4307291215 hasAuthorship W4307291215A5026973034 @default.
• W4307291215 hasAuthorship W4307291215A5032147051 @default.
• W4307291215 hasAuthorship W4307291215A5042816161 @default.
• W4307291215 hasAuthorship W4307291215A5045520775 @default.
• W4307291215 hasAuthorship W4307291215A5047808830 @default.
• W4307291215 hasAuthorship W4307291215A5048312605 @default.
• W4307291215 hasAuthorship W4307291215A5058612575 @default.
• W4307291215 hasAuthorship W4307291215A5061621165 @default.
• W4307291215 hasAuthorship W4307291215A5065463553 @default.
• W4307291215 hasAuthorship W4307291215A5090124860 @default.
• W4307291215 hasConcept C106159729 @default.
• W4307291215 hasConcept C121608353 @default.
• W4307291215 hasConcept C126322002 @default.
• W4307291215 hasConcept C126838900 @default.
• W4307291215 hasConcept C143998085 @default.
• W4307291215 hasConcept C162324750 @default.
• W4307291215 hasConcept C187625094 @default.
• W4307291215 hasConcept C19617505 @default.
• W4307291215 hasConcept C199374082 @default.
• W4307291215 hasConcept C20417620 @default.
• W4307291215 hasConcept C2775842073 @default.
• W4307291215 hasConcept C2779013556 @default.
• W4307291215 hasConcept C2780192828 @default.
• W4307291215 hasConcept C2781406297 @default.
• W4307291215 hasConcept C2989005 @default.
• W4307291215 hasConcept C509974204 @default.
• W4307291215 hasConcept C71924100 @default.
• W4307291215 hasConcept C85393063 @default.
• W4307291215 hasConcept C91602232 @default.
• W4307291215 hasConceptScore W4307291215C106159729 @default.
• W4307291215 hasConceptScore W4307291215C121608353 @default.
• W4307291215 hasConceptScore W4307291215C126322002 @default.
• W4307291215 hasConceptScore W4307291215C126838900 @default.
• W4307291215 hasConceptScore W4307291215C143998085 @default.
• W4307291215 hasConceptScore W4307291215C162324750 @default.
• W4307291215 hasConceptScore W4307291215C187625094 @default.
• W4307291215 hasConceptScore W4307291215C19617505 @default.
• W4307291215 hasConceptScore W4307291215C199374082 @default.
• W4307291215 hasConceptScore W4307291215C20417620 @default.
• W4307291215 hasConceptScore W4307291215C2775842073 @default.
• W4307291215 hasConceptScore W4307291215C2779013556 @default.
• W4307291215 hasConceptScore W4307291215C2780192828 @default.
• W4307291215 hasConceptScore W4307291215C2781406297 @default.
• W4307291215 hasConceptScore W4307291215C2989005 @default.
• W4307291215 hasConceptScore W4307291215C509974204 @default.
• W4307291215 hasConceptScore W4307291215C71924100 @default.
• W4307291215 hasConceptScore W4307291215C85393063 @default.
• W4307291215 hasConceptScore W4307291215C91602232 @default.
• W4307291215 hasIssue "3" @default.
• W4307291215 hasLocation W43072912151 @default.
• W4307291215 hasOpenAccess W4307291215 @default.
• W4307291215 hasPrimaryLocation W43072912151 @default.
• W4307291215 hasRelatedWork W2589983641 @default.
• W4307291215 hasRelatedWork W2769223827 @default.
• W4307291215 hasRelatedWork W2801214390 @default.
• W4307291215 hasRelatedWork W2942602992 @default.
• W4307291215 hasRelatedWork W3007575669 @default.
• W4307291215 hasRelatedWork W3037257784 @default.
• W4307291215 hasRelatedWork W3165855941 @default.
• W4307291215 hasRelatedWork W3183807799 @default.
• W4307291215 hasRelatedWork W4286294110 @default.
• W4307291215 hasRelatedWork W4307291215 @default.

• next